Therapeutic Radionuclides: Biophysical and Radiobiologic Principles

Seminars in Nuclear Medicine

Volumn 38, Issue 5, 2008, Pages 358-366

  Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 IODO 2' DEOXY URIDINE I 125; ACTINIUM 225; ASTATINE 211; BISMUTH 212; BISMUTH 213; COPPER 67; FLOXURIDINE; FREE RADICAL; HOLMIUM 166; IDOXURIDINE; IDOXURIDINE I 123; IODINE 125; IODINE 131; IODOTHIODEOXYTHYMIDINE I 123; LUTETIUM 177; MONOCLONAL ANTIBODY I 131; MONOCLONAL ANTIBODY IN 111; OXYGEN; PHOSPHORUS 32; PHOSPHORUS 33; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RHENIUM 186; RHENIUM 188; STRONTIUM 89; UNCLASSIFIED DRUG; YTTRIUM 90;

ALPHA RADIATION; APOPTOSIS; BREAST CANCER; BYSTANDER EFFECT; CANCER CELL; CANCER RADIOTHERAPY; CELL CLONE; CELL COMMUNICATION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL HYPOXIA; CELL STRUCTURE; CELL SURVIVAL; CHROMATIN; CYTOTOXICITY; DNA DAMAGE; DOSE TIME EFFECT RELATION; DOSIMETRY; DOUBLE STRANDED DNA BREAK; DRUG DISTRIBUTION; ELECTRON; ELECTRON RADIATION; ELECTRON TRANSPORT; ENERGY ABSORPTION; EXTERNAL BEAM RADIOTHERAPY; GAP JUNCTION; GENE TARGETING; HALF LIFE TIME; HUMAN; IN VITRO STUDY; IONIZING RADIATION; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; MAMMAL CELL; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; OVARY CANCER; OXYGEN ENHANCEMENT RATIO; PROSTATE CARCINOMA; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION ENERGY; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SURVIVAL RATE; TREATMENT FAILURE; TUMOR;

BIOPHYSICS; COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; RADIOBIOLOGY; RADIOISOTOPES; RADIOMETRY; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 47749154422     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.05.002     Document Type: Review

References (48)

1. Walicka M.A., Vaidyanathan G., Zalutsky M.R., et al. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res 150 (1998) 263-268
2. Goddu S.M., Howell R.W., and Rao D.V. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 35 (1994) 303-316
3. Kassis A.I. The amazing world of Auger electrons. Int J Radiat Biol 80 (2004) 789-803
4. Cole A. Absorption of 20-eV to 50,000-eV electron beams in air and plastic. Radiat Res 38 (1969) 7-33
5. 35S: theory and application to a cellular model. Radiat Res 84 (1980) 407-425
6. Kassis A.I., Adelstein S.J., Haydock C., et al. Lethality of Auger electrons from the decay of bromine-77 in the DNA of mammalian cells. Radiat Res 90 (1982) 362-373
7. Kassis A.I., Sastry K.S.R., and Adelstein S.J. Intracellular localisation of Auger electron emitters: Biophysical dosimetry. Radiat Prot Dosimetry 13 (1985) 233-236
8. Kassis A.I., and Adelstein S.J. Does nonuniformity of dose have implications for radiation protection?. J Nucl Med 33 (1992) 384-387
9. Barendsen G.W. LET dependence of linear and quadratic terms in dose-response relationships for cellular damage: Correlations with the dimensions and structures of biological targets. Radiat Prot Dosimetry 31 (1990) 235-239
10. Azzam E.I., de Toledo S.M., and Little J.B. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from α-particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA 98 (2001) 473-478
11. Narayanan P.K., Goodwin E.H., and Lehnert B.E. α particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res 57 (1997) 3963-3971
12. Narayanan P.K., LaRue K.E.A., Goodwin E.H., et al. Alpha particles induce the production of interleukin-8 by human cells. Radiat Res 152 (1999) 57-63
13. Iyer R., and Lehnert B.E. Factors underlying the cell growth-related bystander responses to α particles. Cancer Res 60 (2000) 1290-1298
14. Kishikawa H., Wang K., Adelstein S.J., et al. Inhibitory and stimulatory bystander effects are differentially induced by iodine-125 and iodine-123. Radiat Res 165 (2006) 688-694
15. Sgouros G., Knox S.J., Joiner M.C., et al. MIRD continuing education: Bystander and low-dose-rate effects: Are these relevant to radionuclide therapy?. J Nucl Med 48 (2007) 1683-1691
16. Xue L.Y., Butler N.J., Makrigiorgos G.M., et al. Bystander effect produced by radiolabeled tumor cells in vivo. Proc Natl Acad Sci USA 99 (2002) 13765-13770
17. Boyd M., Ross S.C., Dorrens J., et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and Auger electron-emitting radionuclides. J Nucl Med 47 (2006) 1007-1015
18. Humm J.L., and Cobb L.M. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31 (1990) 75-83
19. Humm J.L., Chin L.M., Cobb L., et al. Microdosimetry in radioimmunotherapy. Radiat Prot Dosimetry 31 (1990) 433-436
20. International Commission on Radiation Units and Measurements: Absorbed-Dose Specification in Nuclear Medicine, Report 67. J ICRU 2 (2002) 1-110
21. O'Donoghue J.A. The impact of tumor cell proliferation in radioimmunotherapy. Cancer 73 (1994) 974-980
22. Kocher D.C. Radioactive Decay Data Tables: A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments. Vol DOE/TIC-11026 (1981), National Technical Information Center, US Department of Energy, Springfield, VA
23. International Commission on Radiation Units and Measurements. Stopping Powers and Ranges for Protons and Alpha Particles, Report 49 (1993), International Commission on Radiation Units and Measurements, Bethesda, MD
24. Kassis A.I., Harris C.R., Adelstein S.J., et al. The in vitro radiobiology of astatine-211 decay. Radiat Res 105 (1986) 27-36
25. 212Bi distributed in the growth medium. Radiat Prot Dosimetry 52 (1994) 311-315
26. 3HTdR. Radiat Res 67 (1976) 332-343
27. Bloomer W.D., McLaughlin W.H., Neirinckx R.D., et al. Astatine-211-tellurium radiocolloid cures experimental malignant ascites. Science 212 (1981) 340-341
28. Macklis R.M., Kinsey B.M., Kassis A.I., et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 240 (1988) 1024-1026
29. Zalutsky M.R., McLendon R.E., Garg P.K., et al. Radioimmunotherapy of neoplastic meningitis in rats using an α-particle-emitting immunoconjugate. Cancer Res 54 (1994) 4719-4725
30. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 60 (2000) 6095-6100
31. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 61 (2001) 2008-2014
32. McDevitt M.R., Ma D., Lai L.T., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 (2001) 1537-1540
33. 3H disintegration in the DNA of Chinese hamster cells. Curr Top Radiat Res Q 12 (1977) 408-425
34. Esteban J.M., Schlom J., Mornex F., et al. Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 23 (1987) 643-655
35. Otte A., Mueller-Brand J., Dellas S., et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351 (1998) 417-418
36. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int J Oncol 15 (1999) 1017-1025
37. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97 (2000) 1802-1807
38. 67Cu-2IT-BAT-Lym-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2. Cancer 80 (1997) 2576-2582
39. 125IUdR in mammalian cells: Implications of localized energy deposition by Auger processes. Radiat Res 109 (1987) 78-89
40. Bloomer W.D., McLaughlin W.H., Weichselbaum R.R., et al. Iodine-125-labelled tamoxifen is differentially cytotoxic to cells containing oestrogen receptors. Int J Radiat Biol 38 (1980) 197-202
41. 125I in mammalian cells. Radiat Res 111 (1987) 305-318
42. 125I]iodoHoechst 33342: Contribution of scavengeable effects. Int J Radiat Biol 75 (1999) 1579-1587
43. 111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS): An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 48 (2007) 1357-1368
44. 123I-ITdU-mediated nanoirradiation of DNA efficiently induces cell kill in HL60 leukemia cells and in doxorubicin-, β-, or γ-radiation-resistant cell lines. J Nucl Med 48 (2007) 1000-1007
45. 125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. Int J Radiat Biol 80 (2004) 941-946
46. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. Acta Oncol 35 (1996) 941-945
47. 125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 265 (1977) 620-621
48. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys 21 (1991) 1541-1551